Refine
Year of publication
Document Type
- Article (163)
- Preprint (38)
- Conference Proceeding (4)
- Doctoral Thesis (1)
- Periodical (1)
- Part of Periodical (1)
- Report (1)
- Review (1)
- Working Paper (1)
Is part of the Bibliography
- no (211)
Keywords
- breast cancer (13)
- Mammakarzinom (12)
- Behandlung (8)
- Metastasen (8)
- LHC (7)
- CDK4/6 (6)
- PD1/PDL1 (6)
- Prävention (6)
- Studien (6)
- prevention (6)
- treatment (6)
- metastases (5)
- Breast cancer (4)
- Risiko (4)
- risk (4)
- trials (4)
- ALICE (3)
- ALICE experiment (3)
- Hadron-Hadron Scattering (3)
- metastatic (3)
- neoadjuvant therapy (3)
- pp collisions (3)
- Alpelisib (2)
- Atezolizumab (2)
- Beauty production (2)
- Diagnostik (2)
- Früherkennung (2)
- Galaktografie (2)
- Galaktomosynthese (2)
- HNSCC (2)
- Head and neck cancer (2)
- Katherine (2)
- Lokalrezidiv (2)
- MRI (2)
- MRT (2)
- Machine learning (2)
- Mamma (2)
- Nachsorge (2)
- PARP (2)
- PD1/ PDL1 (2)
- PD‑L1 (2)
- PI3K (2)
- Prognosefaktoren (2)
- Prädiktivfaktoren (2)
- Richtlinie (2)
- Single electrons (2)
- Supportivtherapie (2)
- Surgery (2)
- Tomosynthese (2)
- T‑DM1 (2)
- Ultraschall (2)
- adjuvant therapy (2)
- adjuvante Therapie (2)
- advanced (2)
- alpelisib (2)
- atezolizumab (2)
- breast (2)
- diagnosis (2)
- early breast cancer (2)
- follow‑up (2)
- fortgeschritten (2)
- frühes Mammakarzinom (2)
- galactography (2)
- galactomosynthesis (2)
- guideline (2)
- lapatinib (2)
- local recurrence (2)
- neoadjuvante Therapie (2)
- predictive factors (2)
- prognostic factors (2)
- screening (2)
- studies (2)
- supportive therapy (2)
- tomosynthesis (2)
- trastuzumab (2)
- treatment/therapy (2)
- ultrasound (2)
- 900 GeV (1)
- ATXN2 (1)
- Active middle ear implants (1)
- Advanced breast cancer (1)
- Amyotrophic lateral sclerosis (1)
- Anthropologie (1)
- Antihormone therapy (1)
- Antike (1)
- Arteria ophthalmica (1)
- Artificial Intelligence (1)
- Atoms (1)
- Auditory system (1)
- B cell malignancies (1)
- BCOR (1)
- BCORL1 (1)
- Bibliometrics (1)
- Biodiversity Data (1)
- Biomarker (1)
- Biomonitoring (1)
- Bipolar disorder (1)
- Blindness (1)
- Bone conduction devices (1)
- Bone metastases (1)
- Botanical Collections (1)
- Brain metastasis (1)
- Business strategy in drug development (1)
- C3M (1)
- C4M (1)
- CD74 (1)
- COVID-19 (1)
- CUP (1)
- CVID (1)
- Cancer of unknown primary (1)
- Capecitabine (1)
- Cell membranes (1)
- Cellular microbiology (1)
- Cellular stress (1)
- Central nervous system metastases (1)
- Cervical (1)
- Charm physics (1)
- Chemical biology (1)
- Chemical ecology (1)
- Citation analysis (1)
- Clinical Trials and Observations (1)
- Compact astrophysical objects (1)
- Comparison with QCD (1)
- Completed suicide (1)
- Consensus statement (1)
- Conservation (1)
- Cryoelectron microscopy (1)
- Cryoelectron tomography (1)
- DNA repair (1)
- Diagnostic markers (1)
- Digital breast tomosynthesis (DBT) (1)
- Digital mammography (1)
- Digitization (1)
- Drogenkonsum (1)
- Drogenkriminalität (1)
- Drogenszene (1)
- Drug therapy (1)
- EBV (1)
- Endocrinology (1)
- Environmental chemistry (1)
- Epilepsy (1)
- European Society for Immunodeficiencies (ESID) (1)
- Exosomes (1)
- Extended donor criteria (1)
- FDG-PET/CT (1)
- Femtoscopy (1)
- Filler (1)
- First site of metastatic disease (1)
- Frankfurt <Main> (1)
- Galaxies and clusters (1)
- Gene regulation (1)
- German PID-NET registry (1)
- Glabella (1)
- Global protein synthesis rates (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- HBT (1)
- HER2 c-erbB2 (1)
- HER2-positive (1)
- HER2/neu (1)
- HLA class II (1)
- HLA peptidome (1)
- Hadron production (1)
- Head neck cancer (1)
- Health policy (1)
- Heavy Ions (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Herbaria (1)
- Herder, Johann Gottfried von (1)
- Heregulin (1)
- High-energy astrophysics (1)
- Iceland (1)
- IgG substitution therapy (1)
- Immunophenotyping (1)
- Immunotherapy (1)
- Inclusive spectra (1)
- Induction therapy (1)
- Intensity interferometry (1)
- Ions (1)
- Isoflurane (1)
- Jets (1)
- KCGS (1)
- Kidney diseases (1)
- LTER (1)
- LTP (1)
- Library screening (1)
- Loco-regional control (1)
- Long‐term ecosystem research (1)
- Luciferase (1)
- Lymph node (1)
- Lymphocyte subpopulations (1)
- MM-121 (1)
- Mensch (1)
- Metastatic (1)
- Metastatic breast cancer (1)
- MicroRNAs (1)
- Mid-rapidity (1)
- Mixed hearing loss (1)
- Molecular subtypes (1)
- Monte Carlo simulations (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- Multienzyme complexes (1)
- Myeloid Neoplasia (1)
- NK cell subsets (1)
- NPH insulin (1)
- Nanoscale materials (1)
- Neoadjuvant therapy (1)
- Nuclear modification factor (1)
- Occlusion (1)
- Ophthalmoplegia (1)
- Organ allocation (1)
- PELICAN (1)
- PID prevalence (1)
- PYTHIA (1)
- Paediatrics (1)
- Pancreas transplantation (1)
- Pandemic (1)
- Pathological complete response (1)
- Patterns of care (1)
- Pb–Pb (1)
- Pegylated liposomal doxorubicin (1)
- Perturbative methods (1)
- Philosophische Anthropologie (1)
- Phosphorylation (1)
- Population-based screening (1)
- Prediction of locoregional recurrence (1)
- Proton–proton (1)
- RNA processing (1)
- Radiochemotherapy (1)
- Radiomics (1)
- Radiotherapy (1)
- Recall rate (1)
- Red blood cell transfusion (1)
- Rehabilitation (1)
- Reimarus, Hermann Samuel (1)
- Reimarus, Hermann Samuel: Allgemeine Betrachtungen über die Triebe der Thiere (1)
- Rejection (1)
- Relativistic heavy ion physics (1)
- Research Infrastructure (1)
- Research infrastructure (1)
- Retinal diseases (1)
- Rezeption (1)
- Ribosomal S6 phosphorylation (1)
- Ribosomal translation (1)
- SARS-CoV2 (1)
- SCCHN (1)
- Salivary gland carcinoma (1)
- Scattering of atoms, molecules, clusters & ions (1)
- Scattering theory (1)
- Scientific publishing (1)
- Scientists (1)
- Semantics (1)
- Seribantumab (1)
- Single muons (1)
- Site networks (1)
- Small molecules (1)
- Soziale Kontrolle (1)
- Spinocerebellar ataxia (1)
- Status epilepticus (1)
- Stem-cell therapies (1)
- Suicide attempt (1)
- T-DM1 (1)
- TGFB-induced factor homeobox 1 (1)
- TGIF (1)
- Taxonomy (1)
- Technical data (1)
- Tiere (1)
- Transverse momentum (1)
- Triple negative (1)
- Tumor heterogeneity (1)
- Tumor infiltrating lymphocytes (1)
- Type 2 diabetes (1)
- Validation (1)
- Vesicles (1)
- acute myeloid leukemia (1)
- advanced breast cancer (1)
- aging (1)
- amblyopia (1)
- amyloid precursor protein (1)
- anaemia (1)
- anterior chamber depth changes (1)
- antibiotic therapy (1)
- antihormone therapy (1)
- archeological modeling (1)
- artificial magnetic lattices (1)
- ascites (1)
- basal insulin (1)
- biomarker (1)
- cataract surgery (1)
- chemogenomic set (1)
- chemotherapy (1)
- chloroplast membrane proteins (1)
- circadian variation (1)
- collagen degradation marker (1)
- continuous glucose monitoring (1)
- diabetes (1)
- diabetic macular edema (1)
- diclofenac (1)
- diffusion-weighted magnetic resonance imaging (1)
- drug discovery (1)
- druggable genome (1)
- effective lens position (1)
- elderly patients (1)
- envelope membrane proteome approach comparison (1)
- everolimus (1)
- fluocinolone acetonide (1)
- focused electron beam induced deposition (1)
- gene signature (1)
- head and neck squamous cell carcinoma (1)
- heavy ions (1)
- hippocampus (1)
- human–environment interaction (1)
- hypoglycaemia (1)
- image-based risk modelling (1)
- iron deficiency (1)
- kinase inhibitor (1)
- liver cirrhosis (1)
- loss-of-function (1)
- machine learning (1)
- magnetic nanostructures (1)
- mass spectrometry (1)
- membrane proteome (1)
- meta-analysis (1)
- metastasis (1)
- metastatic renal cell carcinoma (1)
- metformin (1)
- micro-Hall magnetometry (1)
- microdosimetry (1)
- microdosing (1)
- micromagnetic simulations (1)
- mitochondria (1)
- multidrug resistance (1)
- multiplexed immunofluorescence (1)
- nanolesions (1)
- neoadjuvant chemoradiotherapy (1)
- open science (1)
- oral cavity cancer (1)
- oral enzyme combination (1)
- osteoarthritis (1)
- paleoclimate modeling (1)
- paleoenvironment modeling (1)
- paleoenvironment reconstruction (1)
- patient blood management (1)
- pediatric eye screening (1)
- personalised therapy (1)
- pertuzumab (1)
- phase IV (1)
- phenotypic screening (1)
- plant proteomics (1)
- postoperative radiochemotherapy (1)
- postoperative radiotherapy (1)
- predictive biomarker (1)
- pregnancy (1)
- preoperative anaemia management (1)
- preschool health examination (1)
- presynaptic active zone (1)
- primary immunodeficiency (PID) (1)
- propensity score matching (1)
- protein kinase (1)
- pseudoexfoliative syndrome (1)
- radiation oncology (1)
- radiation-induced nanostructures (1)
- radiomic (1)
- randomized controlled trial (1)
- rat (1)
- registry for primary immunodeficiency (1)
- risk stratification (1)
- screening routine (1)
- second-line (1)
- small molecules (1)
- spectra (1)
- surgery (1)
- survival (1)
- understudied kinase (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (93)
- Medizin (82)
- Frankfurt Institute for Advanced Studies (FIAS) (70)
- Informatik (69)
- Geowissenschaften (11)
- Biowissenschaften (9)
- Biochemie und Chemie (7)
- Pharmazie (4)
- Erziehungswissenschaften (3)
- Exzellenzcluster Makromolekulare Komplexe (3)
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1–25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0–88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%—subcutaneous; 29%—intravenous; 1%—unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
Ziele: Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) publiziert und koordiniert wurde, ist es, die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms zu optimieren.
Methoden: Der Aktualisierungsprozess der S3-Leitlinie aus 2012 basierte zum einen auf der Adaptation identifizierter Quellleitlinien und zum anderen auf Evidenzübersichten, die nach Entwicklung von PICO-(Patients/Interventions/Control/Outcome-)Fragen, systematischer Recherche in Literaturdatenbanken sowie Selektion und Bewertung der gefundenen Literatur angefertigt wurden. In den interdisziplinären Arbeitsgruppen wurden auf dieser Grundlage Vorschläge für Empfehlungen und Statements erarbeitet, die im Rahmen von strukturierten Konsensusverfahren modifiziert und graduiert wurden.
Empfehlungen: Der Teil 1 dieser Kurzversion der Leitlinie zeigt Empfehlungen zur Früherkennung, Diagnostik und Nachsorge des Mammakarzinoms: Der Stellenwert des Mammografie-Screenings wird in der aktualisierten Leitlinienversion bestätigt und bildet damit die Grundlage der Früherkennung. Neben den konventionellen Methoden der Karzinomdiagnostik wird die Computertomografie (CT) zum Staging bei höherem Rückfallrisiko empfohlen. Die Nachsorgekonzepte beinhalten Untersuchungsintervalle für die körperliche Untersuchung, Ultraschall und Mammografie, während weiterführende Gerätediagnostik und Tumormarkerbestimmungen bei der metastasierten Erkrankung Anwendung finden.
Purpose: The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast cancer.
Methods: The process of updating the S3 guideline dating from 2012 was based on the adaptation of identified source guidelines which were combined with reviews of evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions and the results of a systematic search of literature databases and the selection and evaluation of the identified literature. The interdisciplinary working groups took the identified materials as their starting point to develop recommendations and statements which were modified and graded in a structured consensus procedure.
Recommendations: Part 1 of this short version of the guideline presents recommendations for the screening, diagnosis and follow-up care of breast cancer. The importance of mammography for screening is confirmed in this updated version of the guideline and forms the basis for all screening. In addition to the conventional methods used to diagnose breast cancer, computed tomography (CT) is recommended for staging in women with a higher risk of recurrence. The follow-up concept includes suggested intervals between physical, ultrasound and mammography examinations, additional high-tech diagnostic procedures, and the determination of tumor markers for the evaluation of metastatic disease.
We have has performed the first measurement of the coherent ψ(2S) photo-production cross section in ultra-peripheral Pb-Pb collisions at the LHC. This charmonium excited state is reconstructed via the ψ(2S) →l+l− and ψ(2S) → J/ψπ+π− decays, where the J/ψ decays into two leptons. The analysis is based on an event sample corresponding to an integrated luminosity of about 22 μb−1. The cross section for coherent ψ(2S) production in the rapidity interval −0.9<y<0.9 is dσcohψ(2S)/dy=0.83±0.19(stat+syst) mb. The ψ(2S) to J/ψ coherent cross section ratio is 0.34+0.08−0.07(stat+syst). The obtained results are compared to predictions from theoretical models.
We have has performed the first measurement of the coherent ψ(2S) photo-production cross section in ultra-peripheral Pb-Pb collisions at the LHC. This charmonium excited state is reconstructed via the ψ(2S) →l+l− and ψ(2S) → J/ψπ+π− decays, where the J/ψ decays into two leptons. The analysis is based on an event sample corresponding to an integrated luminosity of about 22 μb−1. The cross section for coherent ψ(2S) production in the rapidity interval −0.9<y<0.9 is dσcohψ(2S)/dy=0.83±0.19(stat+syst) mb. The ψ(2S) to J/ψ coherent cross section ratio is 0.34+0.08−0.07(stat+syst). The obtained results are compared to predictions from theoretical models.
The transverse momentum (pT) spectrum and nuclear modification factor (RAA) of reconstructed jets in 0–10% and 10–30% central Pb–Pb collisions at √sNN = 2.76 TeV were measured. Jets were reconstructed using the anti-kT jet algorithm with a resolution parameter of R = 0.2 from charged and neutral particles, utilizing the ALICE tracking detectors and Electromagnetic Calorimeter (EMCal). The jet pT spectra are reported in the pseudorapidity interval of |ηjet| < 0.5 for 40 < pT, jet < 120 GeV/c in 0–10% and for 30 < pT, jet < 100 GeV/c in 10–30% collisions. Reconstructed jets were required to contain a leading charged particle with pT > 5 GeV/c to suppress jets constructed from the combinatorial background in Pb–Pb collisions. The leading charged particle requirement applied to jet spectra both in pp and Pb–Pb collisions had a negligible effect on the RAA. The nuclear modification factor RAA was found to be 0.28 ± 0.04 in 0–10% and 0.35 ± 0.04 in 10–30% collisions, independent of pT, jet within the uncertainties of the measurement. The observed suppression is in fair agreement with expectations from two model calculations with different approaches to jet quenching.
We have performed the first measurement of the coherent ψ(2S) photo production cross section in ultraperipheral Pb–Pb collisions at the LHC. This charmonium excited state is reconstructed via the ψ(2S) → l +l − and ψ(2S) → J/ψπ+π− decays, where the J/ψ decays into two leptons. The analysis is based on an event sample corresponding to an integrated luminosity of about 22 μb−1. The cross section for coherent ψ(2S) production in the rapidity interval −0.9 < y < 0.9 is dσcoh ψ(2S)/dy = 0.83±0.19 stat+syst mb. The ψ(2S) to J/ψ coherent cross section ratio is 0.34+0.08 −0.07(stat + syst). The obtained results are compared to predictions from theoretical models.
A measurement of dijet correlations in p–Pb collisions at √sNN = 5.02 TeV with the ALICE detector is presented. Jets are reconstructed from charged particles measured in the central tracking detectors and neutral energy deposited in the electromagnetic calorimeter. The transverse momentum of the full jet (clustered from charged and neutral constituents) and charged jet (clustered from charged particles only) is corrected event-by-event for the contribution of the underlying event, while corrections for underlying event fluctuations and finite detector resolution are applied on an inclusive basis. A projection of the dijet transverse momentum, kTy = pch+ne T,jet sin(ϕdijet) with ϕdijet the azimuthal angle between a full and charged jet and pch+ne T,jet the transverse momentum of the full jet, is used to study nuclear matter effects in p–Pb collisions. This observable is sensitive to the acoplanarity of dijet production and its potential modification in p–Pb collisions with respect to pp collisions. Measurements of the dijet kTy as a function of the transverse momentum of the full and recoil charged jet, and the event multiplicity are presented. No significant modification of kTy due to nuclear matter effects in p–Pb collisions with respect to the event multiplicity or a PYTHIA8 reference is observed.
The measurement of the mass differences for systems bound by the strong force has reached a very high precision with protons and anti-protons1,2. The extension of such measurement from (anti-)baryons to (anti-)nuclei allows one to probe any difference in the interactions between nucleons and anti-nucleons encoded in the (anti-)nuclei masses. This force is a remnant of the underlying strong interaction among quarks and gluons and can be described by effective theories3, but cannot yet be directly derived from quantum chromodynamics. Here we report a measurement of the difference between the ratios of the mass and charge of deuterons (d) and anti-deuterons (), and 3He and nuclei carried out with the ALICE (A Large Ion Collider Experiment)4 detector in Pb–Pb collisions at a centre-of-mass energy per nucleon pair of 2.76 TeV. Our direct measurement of the mass-over-charge differences confirms CPT invariance to an unprecedented precision in the sector of light nuclei5,6. This fundamental symmetry of nature, which exchanges particles with anti-particles, implies that all physics laws are the same under the simultaneous reversal of charge(s) (charge conjugation C), reflection of spatial coordinates (parity transformation P) and time inversion (T).
Charged jet production cross sections in p–Pb collisions at √sNN=5.02 TeV measured with the ALICE detector at the LHC are presented. Using the anti-kT algorithm, jets have been reconstructed in the central rapidity region from charged particles with resolution parameters R=0.2 and R=0.4. The reconstructed jets have been corrected for detector effects and the underlying event background. To calculate the nuclear modification factor, RpPb, of charged jets in p–Pb collisions, a pp reference was constructed by scaling previously measured charged jet spectra at s=7 TeV. In the transverse momentum range 20≤pT,chjet≤120 GeV/c, RpPb is found to be consistent with unity, indicating the absence of strong nuclear matter effects on jet production. Major modifications to the radial jet structure are probed via the ratio of jet production cross sections reconstructed with the two different resolution parameters. This ratio is found to be similar to the measurement in pp collisions at √s=7 TeV and to the expectations from PYTHIA pp simulations and NLO pQCD calculations at √sNN=5.02 TeV.